TY - JOUR
T1 - Molecular therapies in hepatocellular carcinoma
T2 - What can we target?
AU - Galuppo, Roberto
AU - Ramaiah, Dinesh
AU - Ponte, Oscar Moreno
AU - Gedaly, Roberto
PY - 2014/8
Y1 - 2014/8
N2 - Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.
AB - Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.
KW - Epidermal growth factor
KW - Hepatocellular carcinoma
KW - Liver cancer stem cells
KW - Ras/Raf/MAPK
KW - Sorafenib
UR - http://www.scopus.com/inward/record.url?scp=84905571686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905571686&partnerID=8YFLogxK
U2 - 10.1007/s10620-014-3058-x
DO - 10.1007/s10620-014-3058-x
M3 - Review article
C2 - 24573715
AN - SCOPUS:84905571686
SN - 0163-2116
VL - 59
SP - 1688
EP - 1697
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 8
ER -